Congressional analysis: Pay-for-delay ban would save taxpayers $4.8B over 10 years
This article was originally published in Scrip
Executive Summary
Senators Herb Kohl (Democrat-Wisconsin) and Charles Grassley (Republican-Iowa) have been backed up by a new report from the US Congressional Budget Office (CBO) in the lawmakers' pursuit to get legislation enacted that would ban patent settlements in which innovator drug makers pay generic manufacturers to delay the entrance into the marketplace of their cheaper generic versions.